Inclusion Criteria:

- Hospital in- or out patients

- Either sex

- 18 to 75 years of age

- With hepatocellular carcinoma treated successfully with surgical resection or
percutaneous ablative treatment within 4 and 8 weeks, respectively, prior to
inclusion.

- All patients must give their signed informed consent to join the study.

Exclusion Criteria:

- Patients previously treated with any anti-cancer therapy for HCC except for surgical
resection and percutaneous ablative therapy

- Patients treated with chemotherapy or other anti-cancer therapy (except surgical
resection or percutaneous ablative treatment) in the previous 4 weeks

- Patients with another primary tumor except basocellular carcinoma of the skin or in
situ carcinoma of the cervix within the last 2 years

- With a history of renal stone(s)

- With a life expectancy < 3 months

- WHO performance status 3 or 4.

- Patients with hypercalcemia (ionised serum calcium > 1.35 mmol/l or albumin corrected
serum calcium > 2.68 mmol/l), previous/current calcium metabolic disease, taking
calcium-lowering therapy or medication known to affect systemic calcium metabolism,
or with marked laboratory abnormalities.

- Patients with recurrent hepatocellular carcinoma, with known extrahepatic metastases,
Okuda stage III disease and patients with a Child-Pugh score of C are also excluded.